Professor, Medicine, Emory University School of Medicine
Nephrology
Dr. Arlene B. Chapman, MD
|
|
Give Review
Arlene Chapman practices Nephrology. She researched medicine at Georgetown University School of Medicine. Georgetown University School of Medicine has a rank of 49 in research and a 84 in primary care Doctor Arlene B. Chapman, MD is also published. She has 87 publications published. The lastest publication: "Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.' Doctor Arlene B. Chapman, MD is registered with Medicare and accepts Medicare payments.
Publications
- Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
- Association of Branched and Aromatic Amino Acids Levels With Metabolic Syndrome and Impaired Fasting Glucose in Hypertensive Patients.
- Liver involvement in early autosomal-dominant polycystic Kidney disease.
- Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease.
- Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease.
- Predictors for Glucose Change in Hypertensive Participants Following Short-term Treatment With Atenolol or Hydrochlorothiazide.
- Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated With hydrochlorothiazide.
- Is a Diabetes-Linked Amino Acid Signature associated with Beta Blocker-Induced Impaired Fasting Glucose?
- Baseline predictors of central aortic blood pressure: A PEAR substudy.
- Impact of CYP2D6 polymorphisms on clinical efficacy & tolerability of metoprolol tartrate.
- Hydrochlorothiazide-induced hyperuricaemia in the Pharmacogenomic Evaluation of AntiHypertensive Responses (PEAR) study.
- PROX1 Gene Variant is Associated With Fasting Glucose Change After Antihypertensive Treatment.
- Association of KCNJ1 variation with change in fasting glucose and new onset Diabetes during HCTZ treatment.
- Genomic association analysis of common variants influencing antiHypertensive response to hydrochlorothiazide.
- Economic burden and resource use associated with autosomal dominant polycystic Kidney disease among a medicare population.
- The Role of Plasma Renin Activity, Age, and Race in Selecting Effective Initial Drug Therapy for Hypertension.
- Segmentation of Individual Renal Cysts from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease.
- Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans.
- Impact of Genetic Polymorphisms of SLC2A2, SLC2A5, and KHK on Metabolic Phenotypes in Hypertensive Individuals.
- Association of variants in NEDD4L With blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated With thiazide diuretics.
- The fetal environment: a critical phase that determines future renal outcomes in autosomal dominant polycystic Kidney disease.
- Evaluation of urine biomarkers of Kidney injury in polycystic Kidney disease.
- Analysis of baseline parameters in the HALT polycystic Kidney disease trials.
- Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and Atenolol.
- Imaging approaches to patients with polycystic Kidney disease.
- Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study.
- Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antiHypertensive-treated patients.
- Renal CD14 expression correlates with the progression of cystic Kidney disease.
- Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for Hypertension.
- Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide.
- Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols.
- Impact of abdominal obesity on incidence of adverse metabolic effects associated With antihypertensive medications.
- Comparison of office, ambulatory, and home blood pressure antiHypertensive response to atenolol and hydrochlorthiazide.
- The HALT polycystic Kidney disease trials: design and implementation.
- Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antiHypertensive drug therapy: the GERA study.
- Renal volume in children With ADPKD: size matters.
- Pharmacogenomics of antiHypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of AntiHypertensive Responses (PEAR) study.
- Quality of life in autosomal dominant polycystic Kidney disease patients not yet on dialysis.
- Improving clinical trial design for inquiries into the mechanisms of cyst growth in ADPKD.
- Nurturing passion in a time of academic climate change: the modern-day challenge of junior faculty development.
- Genomic association analysis suggests chromosome 12 locus influencing antiHypertensive response to thiazide diuretic.
- Approaches to testing new treatments in autosomal dominant polycystic Kidney disease: insights from the CRISP and HALT-PKD studies.
- Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential Hypertension.
- Autosomal dominant polycystic Kidney disease: time for a change?
- Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic Kidney disease.
- Volume progression in autosomal dominant polycystic Kidney disease: the major factor determining clinical outcomes.
- Sonographic assessment of the severity and progression of autosomal dominant polycystic Kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Di...
- WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic.
- Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in Hypertensive subjects.
- A multilocus approach to the antiHypertensive pharmacogenetics of hydrochlorothiazide.
- Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide.
- Cystic and inherited Kidney diseases.
- The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic Kidney disease.
- Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide.
- Recurrence of intracranial aneurysms in autosomal-dominant polycystic Kidney disease.
- Cystic disease in women: clinical characteristics and medical management.
- Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide.
- Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio.
- Reproducibility of blood pressure response to hydrochlorothiazide.
- Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential Hypertension.
- A novel simple method for determining CYP2D6 gene copy number and identifying allele(s) With duplication/multiplication.
- Medical resource utilization and costs associated with autosomal dominant polycystic Kidney disease in the USA: a retrospective matched cohort analysis of private insu...
- Large-scale gene-centric analysis identifies polymorphisms for resistant Hypertension.
- Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environment.
- Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of AntiHypertensive Responses (PEAR) Study.
- Nephrology fellows show consistent use of, and improved knowledge from, a nephrologist-programmed teaching instrument.
- A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic Kidney disease.
- Polycystic Kidney disease: The cadence of Kidney growth in ADPKD.
- Primary aldosteronism in diabetic subjects With resistant hypertension.
- Tolvaptan in autosomal dominant polycystic Kidney disease: three years'' experience.
- Renal arterial blood flow measurement by breath-held MRI: Accuracy in phantom scans and reproducibility in healthy subjects.
- Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic Kidney disease: the Consortium for Radiologic Imaging Studies of Polycyst...
- Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic Kidney disease.
- MRI-based Kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement.
- Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antiHypertensive respon...
- Comprehensive molecular diagnostics in autosomal dominant polycystic Kidney disease.
- Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic Kidney disease.
- Characterization of large rearrangements in autosomal dominant polycystic Kidney disease and the PKD1/TSC2 contiguous gene syndrome.
- Renal structure in early autosomal-dominant polycystic Kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
- Potentially modifiable factors affecting the progression of autosomal dominant polycystic Kidney disease.
- Prospects for mTOR inhibitor use in patients with polycystic Kidney disease and hamartomatous diseases.
- Nephrogenic systemic fibrosis versus contrast-induced nephropathy: risks and benefits of contrast-enhanced MR and CT in Renally impaired patients.
- Treatment of autosomal dominant polycystic Kidney disease (ADPKD): the new horizon for children with ADPKD.
- Comparison of methods for determining renal function decline in early autosomal dominant polycystic Kidney disease: the consortium of radiologic imaging studies of pol...
- Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic Kidney disease.
- Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic Kidney disease: results of a seven-year prospective rando...
Schools
McMaster University
Georgetown University
Conditions Treated
- Acidosis
- Acute Kidney Failure
- Chronic Kidney Diseases
- Congenital Cystic Kidney Disease
- View All
Doctors Specialties
- Nephrology
Accepted Insurances
Education
-
Georgetown University School of Medicine
Hospital
-
Emory University Hospital Midtown -
Emory University Hospital -
Grady Memorial Hospital
Drug Facts
| NPI NUMBER | 1982614921 | |
| NPPES Provider LastName | CHAPMAN | |
| NPPES Provider FirstName | ARLENE | |
| NPPES Provider ZIPCode | 303221013 | |
| NPPES Provider State | GA | |
| Specialty Description | Nephrology | |
| Total Claim Count | 217.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1982614921 |
| Last Name Of The Provider | CHAPMAN |
| First Name Of The Provider | ARLENE |
| View All |
Similar Doctors
|
|
Dr. Gregory B. Knowlton, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harold A. Franch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ibironke W. Apata, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Janice I. Lea, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ali Kashkouli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dona T. Wu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Titilayo O. Ilori, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sammy M. Mugambi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeanie Park, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evelyn C. Lewis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barry J. Rosenbaum, MD |